Structure Therapeutics (GPCR) vs Mineralys Therapeutics (MLYS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Structure Therapeutics (GPCR) has outperformed Mineralys Therapeutics (MLYS) over the past year, losing 9.8% versus a loss of 41.3%. Mineralys Therapeutics is the larger company by market cap ($1.98 billion vs $1.83 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GPCR | MLYS |
|---|---|---|
| Share price | $25.67 | $22.38 |
| Market cap | $1.83B | $1.98B |
| 1-day change | -3.79% | +1.31% |
| YTD return | -63.09% | -39.13% |
| 1-year return | -9.77% | -41.34% |
| EPS (TTM) | $-3.03 | $-4.22 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $94.90 | $47.65 |
| 52-week low | $25.09 | $21.46 |
| Distance from 52-week high | -72.95% | -53.03% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +312.08% | +116.71% |
| Average volume | 957.51K | 1.03M |
| Shares outstanding | 71.31M | 88.41M |
| Employees | 281 | 76 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GPCR has outperformed MLYS by 31.6 percentage points over the past year.
- The two companies sit in different sectors: Structure Therapeutics in Healthcare and Mineralys Therapeutics in Health Care.
About Structure Therapeutics
GPCR stock →Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions.
Healthcare · Biotechnology · 281 employees
About Mineralys Therapeutics
MLYS stock →Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea.
Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees
GPCR vs MLYS FAQ
Which is bigger, Structure Therapeutics or Mineralys Therapeutics?
Mineralys Therapeutics (MLYS) is larger, with a market capitalization of $1.98B compared with $1.83B for Structure Therapeutics (GPCR).
Which stock has performed better over the past year, GPCR or MLYS?
GPCR returned -9.77% over the past 12 months, compared with -41.34% for MLYS (price return, excluding dividends). Past performance does not predict future results.
Are Structure Therapeutics and Mineralys Therapeutics in the same industry?
No. Structure Therapeutics is in the Healthcare sector, while Mineralys Therapeutics is in Health Care.